Detection of colorectal cancer using 18F-FLT PET: Comparison with 18F-FDG PET

Nuclear Medicine Communications

Volumn 30, Issue 11, 2009, Pages 841-845

  Yamamotoa, Yuka ^a   Kameyamaa, Reiko ^a   Izuishib, Kunihiko ^a   Takebayashib, Ryusuke ^a   Hagiikeb, Masanobu ^a   Asakurac, Masato ^a   Habad, Reiji ^a   Nishiyamaa, Yoshihiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

18F Fluorothymidine; 18F Fluoro D Glucose; Colorectal Cancer; Ki 67; Positron Emission Tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POSITRON EMISSION TOMOGRAPHY; RECTUM CANCER;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DIDEOXYNUCLEOSIDES; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 73249137544     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328330294d     Document Type: Article

References (23)

1. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332
2. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43:492-499
3. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388-395 (Pubitemid 34072520)
4. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998; 4:1334-1336
5. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43:1210-1217
6. 18F-FDG. J Nucl Med 2003; 44:1426-1431
7. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-3332
8. Buck AK, Hetzel M, Schirrmeister H, Halter G, Mö ller P, Kratochwil C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005; 32:525-533
9. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-Fluorothymidine and 18F-Fluorodeoxyglucose-positron emission tomography. Chest 2006; 129:393-401
10. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30:1407-1412
11. 18F-FDG PET. J Nucl Med 2004; 45:226-231
12. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31:720-724
13. 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46:400-404
14. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52:1602-1606
15. 18F]fluoro-2-deoxy D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994
16. 18F]3-deoxy-3-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007; 34:878-883
17. Greene F, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag ew York, Inc; 2002
18. 18F]FLT). J Radioanal Nucl Chem 2000; 24:843-846
19. Costa A, Silvestrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, et al. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer 1996; 73:914-919
20. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182:311-322
21. Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E, Tubiana-Hulin M, et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002; 94:2151-2159
22. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44:2027-2032
23. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63:3791-3798